This week, Asphalion experts Marta Rayo Lunar and Marta Morales participated in the 12-month meeting of the EU H2020 project In2sight, where Asphalion is the regulatory partner. The partners were able to discuss the advances made during this first year.
The goal of the project is to foster an unprecedented breakthrough in in-vivo optical imaging that will radically renew the biocompatibility tests of biomaterials. This technology will recast our thinking of biomaterial validation, allowing unprecedented quantitative and longitudinal analyses of the host inflammatory response to the implant.
Furthermore, the project will allow unique quantification of the immune reaction to biomaterials at the cellular level (scientific impact), largely reducing the ethical burden of the research and the costs of biomaterial discovery (economic impact), and will Refine and Reduce protocols for biocompatibility on a single revolutionary device (regulatory impact).
Have a look at the project´s website to get to know more about In2sight:
For further information, you can contact us at: info@asphalion.com
